PRLD
Closed
Prelude Therapeutics inc
0.8
0.0 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 0.8094
Day's Range: 0.78 - 0.837999
Send
sign up or login to leave a comment!
When Written:
7.13
Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of small molecule therapies for cancer and other diseases. The company was founded in 2016 and is headquartered in Wilmington, Delaware.
Prelude's lead candidate, PRT543, is a potent and selective inhibitor of the protein kinase enzyme known as ERK. ERK plays a critical role in cell signaling pathways that are dysregulated in many types of cancer. PRT543 is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors and hematologic malignancies.
In addition to PRT543, Prelude has a pipeline of preclinical programs targeting other oncology targets, including KRAS, SOS1, and SHP2. The company also has a collaboration with Takeda Pharmaceutical Company to develop small molecule therapies for cancer and other diseases.
Prelude is led by a team of experienced biotech executives and scientists, including CEO and co-founder Kris Vaddi, who previously held leadership roles at Pharmacyclics and AbbVie. The company has raised over $200 million in funding from investors, including OrbiMed Advisors, BVF Partners, and Takeda Ventures.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Prelude's lead candidate, PRT543, is a potent and selective inhibitor of the protein kinase enzyme known as ERK. ERK plays a critical role in cell signaling pathways that are dysregulated in many types of cancer. PRT543 is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors and hematologic malignancies.
In addition to PRT543, Prelude has a pipeline of preclinical programs targeting other oncology targets, including KRAS, SOS1, and SHP2. The company also has a collaboration with Takeda Pharmaceutical Company to develop small molecule therapies for cancer and other diseases.
Prelude is led by a team of experienced biotech executives and scientists, including CEO and co-founder Kris Vaddi, who previously held leadership roles at Pharmacyclics and AbbVie. The company has raised over $200 million in funding from investors, including OrbiMed Advisors, BVF Partners, and Takeda Ventures.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!